https://www.selleckchem.com/products/gdc-0994.html
Long-term, 45.1% of eyes achieved 20/50 or better, while 27.1% were 20/200 or worse. Of the treated patients, 61.2% received monotherapy with no difference in visual acuity outcomes or number of injections between the agents used. OCT analysis showed decreased fluid from initial to final follow-up visit 70.1-15.6% with sub-retinal fluid (SRF) and 47.3-18.8% with intra-retinal fluid (IRF) with no difference between the agents were used. This study demonstrates that most patients (74%) improve or maintain visual acuity long-term using a
Gefällt mir
Kommentar
Teilen
